

SUPPORTING INFORMATION

Metabolic labelling of cancer cells with glycodendrimers stimulate immune-mediated cytotoxicity.

David Goyard,^a Peremobowei Iyanu Diriwari,^a and Nathalie Berthet ^{*a}




Figure S 1. Flow cytometry analysis of BT-549 metabolically labelled with various concentrations of Ac₄ManNAz, followed by SPAAC conjugation to 50 μ M DBCO-PEG₄-Fluor 545. As control, cells without any treatment and non azido-labelled cells were used.




Figure S 2. DBCO-ARM1, 4 and 16 coupling to azido groups exposed at the BT-549 cell-surface. Azido labelled cells or unlabelled cells were treated with DBCO-ARMs or DBCO-PEG (10-0,1 µM). SPAAC coupling of the DBCO-conjugates was revealed using anti-Rha IgM naturally present in HS and fluorescent secondary antibody. Cell fluorescence was analysed by flow cytometry. Data are presented as mean \pm SD (n = 3).




Figure S 3. Dose-response curve of the fluorescence of BT-549 cells metabolically labelled with the azido sugar Ac₄ManNAz, followed by SPAAC conjugation to DBCO-ABM16 at various concentrations (0 µM, 0,1 µM, 0,5 µM, 5 µM, 10 µM). Fluorescence was analysed by flow cytometry.

Compound characterizations

Compound **DBCO-ARM1**




Figure S 4. Analytical RP-HPLC spectrum of compound **DBC0-ABM1** (5-100% B in 15 minutes)




Figure S 5. Theoretical (top) and measured (bottom) HRMS spectrum of compound **DBC0-ABM1**




Figure S 6. ^1H NMR spectrum of compound **DBCO-ABM1** (D_2O , 500 MHz)

Compound **DBCO-ABM4**




Figure S 7. Analytical RP-HPLC spectrum of compound **DBCO-ABM4** (5-100% B in 15 minutes)




Figure S 8. Theoretical (top) and measured (bottom) HRMS spectrum of compound **DBCO-ABM4**




Figure S 9. ^1H NMR spectrum of compound **DBCO-ABM4** (D_2O , 500 MHz)

Compound **DBCO-ABM16**





Figure S 10. Analytical RP-HPLC spectrum of compound **DBCO-ARM16** (0-80% B in 15 minutes)



Q1P076C #116-179 RT: 3.47-5.28 AV: 64 NL: 1.42E5
 T: FTMS + p ESI Full ms [1100.00-2000.00]




Figure S 11. Theoretical (top) and measured (bottom) HRMS spectrum of compound **DBCO-ARM16**




Figure S 12. ^1H NMR spectrum of compound **DBCO-ABM16** (D_2O , 500 MHz)